Bringing Gene Therapies to Market

Article

Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.

The approval of the first gene therapies and technology advances have spurred research and investment for new treatments and provided hope for patients. Researchers are now talking about “cures” versus “treatments,” says Eric Langer, managing partner, BioPlan Associates, in an interview with BioPharm International. Turning clinical processes into an operational process will prove challenging.

Recent Videos
Behind the Headlines, Episode 10
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content